U.S. stocks advanced cautiously Monday as investors braced for a wave of corporate earnings reports, while crude oil prices tumbled sharply. The focus remains on key tech results and evolving geopolitical developments affecting global trade and energy markets.
A recent adjustment to Airgain's price target by analysts reflects a broader reassessment of the wireless connectivity specialist's prospects, underscoring how evolving narratives, rather than single events, are reshaping investor views on the stock.
Micron Technology shares surged again Monday, fueled by a new analyst report highlighting strong demand for its high-bandwidth memory chips and forecasting a significant rise in DRAM prices through 2026.
A recent analyst price target update for Tesla, devoid of specific figures, has reignited debate over the core drivers of the stock's story. The focus is shifting from pure growth metrics to the underlying expectations and perceived risks surrounding its business model and long-term strategy.
A significant reset in CareCloud's (CCLD) price target by analysts is prompting a fresh look at the healthcare IT firm's risk-reward profile. This shift reflects evolving perspectives on the company's trajectory and market position. We examine the catalysts for this change and its implications for investors.
New federal data reveals a significant year-over-year jump in energy costs for November, with natural gas prices soaring and electricity rates climbing, squeezing household budgets amid fluctuating demand and generation patterns.
Barrick Gold Corporation is strategically ramping up gold production to capitalize on high prices while simultaneously expanding its copper portfolio as a long-term hedge. The mining giant is also channeling robust profits back to investors through enhanced dividends and buybacks, following a period of stellar stock performance.
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Shoppers are bracing for another wave of price increases as new import taxes take effect, targeting a range of everyday items from spirits to seafood. Experts warn the hikes will squeeze household budgets and force tough choices at the supermarket.
Goldman Sachs raises Sweetgreen's price target to $5.60, citing policy tailwinds for consumer spending, even as it maintains a Sell rating. The salad chain's expansion and strong revenue growth continue to draw investor attention.
Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.
Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.
Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
Despite a 14% share price decline over the past quarter, Associated British Foods (LON:ABF) demonstrates robust underlying financial health, driven by strong earnings growth and efficient capital reinvestment, suggesting potential for a market correction.
ABB's shares surged 10% following its annual results, with earnings per share exceeding forecasts. Analysts have raised their price target to CHF 60.30 and project accelerated revenue growth ahead of industry peers.
Despite a robust 57% return over three years, a deep dive into Warby Parker's financials reveals a significant disconnect between its current share price and intrinsic value estimates, raising questions about its growth trajectory justifying the premium.
